Eli Lilly R&D decreased by 7.7% to $3.51B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 28.4%, from $2.73B to $3.51B. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 17.8% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Detailed definition
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Peer comparison
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
Metric ID:
research_and_developmentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.66B | $1.71B | $1.90B | $1.61B | $1.78B | $1.80B | $2.00B | $1.99B | $2.36B | $2.41B | $2.56B | $2.52B | $2.71B | $2.73B | $3.02B | $2.73B | $3.34B | $3.47B | $3.80B | $3.51B |
| QoQ Change | — | +3.0% | +11.3% | -15.2% | +10.7% | +1.2% | +10.7% | -0.5% | +18.7% | +2.2% | +6.4% | -1.5% | +7.5% | +0.8% | +10.6% | -9.6% | +22.0% | +3.9% | +9.7% | -7.7% |
| YoY Change | — | — | — | — | +7.7% | +5.7% | +5.1% | +23.3% | +32.2% | +33.6% | +28.4% | +27.1% | +15.1% | +13.5% | +18.0% | +8.4% | +23.0% | +26.8% | +25.8% | +28.4% |
Range$1.61B – $3.80B
CAGR+17.1%
Avg YoY Growth+20.1%
Median YoY Growth+23.2%
Product Breakdown
| Segment | Q1 '25 |
|---|---|
| Late-stage | $1.74B |
| Early-stage | $990.00M |
| Total | $2.73B |
R&D at Other Companies
Frequently Asked Questions
- What is Eli Lilly's r&d?
- Eli Lilly (LLY) reported r&d of $3.51B in Q1 2026.
- How has Eli Lilly's r&d changed year-over-year?
- Eli Lilly's r&d increased by 28.4% year-over-year, from $2.73B to $3.51B.
- What is the long-term trend for Eli Lilly's r&d?
- Over 4 years (2021 to 2025), Eli Lilly's r&d has grown at a 17.8% compound annual growth rate (CAGR), from $6.93B to $13.34B.
- What does r&d mean?
- The money spent on creating new products or improving existing ones to drive future growth.